Increased reactive oxygen species (ROS) generation and the consequent oxidative damage are involved in the development of several diseases, including autoimmune diseases. Graves’ disease is an autoimmune disorder characterized by hyperthyroidism and, less frequently, orbitopathy. Hyperthyroidism is characterized by increased oxidative stress. Untreated hyperthyroidism is associated with an increase of several parameters of oxidative stress and in most studies (but not all) by an increase of antioxidant defense enzymes. Restoration of euthyroidism with antithyroid drug is associated with a reversal of the biochemical abnormalities associated with oxidative stress. Animal and human studies suggest that increased ROS may directly contribute to some clinical manifestation of the disease, including orbitopathy. Antioxidants administered alone improve some clinical signs and symptoms of hyperthyroidism and, when associated with antithyroid drugs, induce a more rapid control of clinical manifestations and a faster achievement of euthyroidism. A large randomized clinical trial has shown that antioxidant supplementation (selenium) may also be beneficial for mild Graves’ orbitopathy.

Keywords:
Hyperthyroidism, Graves’ orbitopathy, Antithyroid drugs, Selenium
1.
Halliwell B, Gutteridge JM: Lipid peroxidation, oxygen radicals, cell damage, and antioxidant therapy. Lancet 1984;1:1396–1397.
2.
Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J: Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44–84.
3.
Song Y, Driessens N, Costa M, De Deken X, Detours V, Corvilain B, Maenhaut C, Dalton TP, Shertzer HG, Puga A: Regulation of gene expression by reactive oxygen. Ann Rev Pharmacol Toxicol 1999;39:67–101.
4.
Halliwell B, Gutteridge JMC: Cellular responses to oxidative stress: adaptation, damage, repair, senescence and death; in: Free Radicals in Biology and Medicine, ed 4. New York, Oxford University Press, 2007, p 187–267.
5.
Venditti P, Di Meo S: Thyroid hormone-induced oxidative strees. Cell Mol Life Sci 2006;63:414–434.
6.
Miot F, Van Sande J, Many MC, Dumont JE: Roles of hydrogen peroxide in thyroid physiology and disease. J Clin Endocrinol Metab 2007;92:3764–3773.
7.
Zarkovic M: The role of oxidative stress on the pathogenesis of Graves’ disease. J Thyroid Res 2012;2012:302537.
8.
Asayama K, Dobashi H, Hayashibe H, Megata Y, Kato K: Lipid peroxidation and free radical scavengers in thyroid dysfunction in the rat: a possible mechanism of injury to hearth and skeletal muscle in hyperthyroidism. Endocrinology 1987;121:2112–2118
9.
Yamada T, Mishima T, Sakamoto M, Sugiyama M, Matsunaga S, Wada M: Oxidation of myosin heavy chain and reduction in force production in hyperthyroid rat soleus. J Appl Physiol 2006;100:1520–1526.
10.
Seven A, Seymen O, Hatemi S, Hatemi H, Yigit G, Candan G: Antioxidant status in experimental hyperthyroidism: effect of vitamin E supplementation. Clin Chim Acta 1996;256:65–74.
11.
Araujo AS, Ribeiro MF, Enzveiler A, Schenkel P, Fernandes TR, Partata WA, Irigoyen MC, Llesuy S, Belló-Klein A: Myocardial antioxidant enzyme activities and concentration and glutathione metabolism in experimental hyperthyroidism. Mol Cell Endocrinol 2006;249:133–139.
12.
Moulakakis KG, Poulakou MV, Paraskevas KI, Dontas I, Vlachos IS, Sokolis DP, Dosios T, Karayannacos PE, Perrea D: Hyperthyroidism is associated with increased aortic oxidative DNA damage in a rat model. In Vivo 2007;21:1021–1026.
13.
Asayama K, Dobashi K, Hayashibe H, Kato K: Vitamin E protects against thyroxine-induced acceleration of lipid peroxidation in cardiac and skeletal muscles in rats. J Nutr Sci Vitaminol (Tokyo) 1989;35:407–418.
14.
Videla LA, Sir T, Wolff C: Increased lipid peroxidation in hyperthyroid patients: suppression by propylthiouracil treatment. Free Radic Res Commun 1988;5:1–10.
15.
Wilson R, Chopra M, Bradley H, McKillop JH, Smith WE, Thomson JA: Free radicals and Graves’ disease: the effects of therapy. Clin Endocrinol (Oxf) 1989;30:429–433.
16.
Adali M, Inal-Erden M, Akalin A, Efe B: Effects of propylthiouracil, propranolol, and vitamin E on lipid peroxidation and antioxidant status in hyperthyroid patients. Clin Biochem 1999;32:363–367.
17.
Bianchi G, Solaroli E, Zaccheroni V, Grossi G, Bargossi AM, Melchionda N, Marchesini G: Oxidative stress and anti-oxidant metabolites in patients with hyperthyroidism: effect of treatment. Horm Metab Res 1999;31:620–624.
18.
Komosinska-Vassev K, Olczyk K, Kucharz EJ, Marcisz C, Winsz-Szczotka K, Kotulska A: Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves’ disease during therapy. Clin Chim Acta 2000;300:107–117.
19.
Guerra LN, Moiguer S, Karner M, de Molina MC, Sreider CM, Burdman JA: Antioxidants in the treatment of Graves disease. IUBMB Life 2001;51:105–109.
20.
Abalovich M, Llesuy S, Gutierrez S, Repetto M: Peripheral parameters of oxidative stress in Graves disease: the effect of methimazole and 131I iodine treatment. Clin Endocrinol (Oxf) 2003;59:321–327.
21.
Bednarek J, Wysocki H, Sowiński J: Oxidative stress peripheral parameters in Graves’ disease: the effect of methimazole treatment in patients with and without infiltrative ophthalmopathy. Clin Biochem 2005;38:13–18.
22.
Guerra LN, Rios de Molina M del C, Miler EA, Moiguer S, Karner M, Burdman JA: Antioxidants and methimazole in the treatment of Graves’ disease: effect on urinary malondialdehyde levels. Clin Chim Acta 2005;352:115–120.
23.
Rybus-Kalinowska B, Zwirska-Korczala K, Kalinowski M, Kukla M, Birkner E, Jochem J: Activity of antioxidative enzymes and concentration of malondialdehyde as oxidative status markers in women with newly diagnosed Graves-Basedow disease and after thiamazole therapy leading to euthyroidism. Pol Arch Med Wewn 2008;118:420–425.
24.
Aslan M, Cosar N, Celik H, Aksoy N, Dulger AC, Begenik H, Soyoral YU, Kucukoglu ME, Selek S: Evaluation of oxidative status in patients with hyperthyroidism. Endocrine 2011;40:285–289
25.
Cetinkaya A, Kurutas EB, Buyukbese MA, Kantarceken B, Bulbuloglu E: Levels of malondialdehyde and superoxide dismutase in subclinical hyperthyroidism. Mediators Inflamm 2005;2005:57–59.
26.
Weetman AP: Effect of the anti-thyroid drug methimazole on interleukin-1 and interleukin-2 levels in vitro. Clin Endocrinol (Oxf) 1986;25:133–142.
27.
Whiteman M, Halliwell B: Thiourea and dimethylthiourea inhibit peroxynitrite-dependent damage: nonspecificity as hydroxyl radical scavengers. Free Radic Biol Med 1997;22:1309–1312.
28.
Mano T, Shinohara R, Iwase K, Kotake M, Hamada M, Uchimuro K, Hayakawa N, Hayashi R, Nakai A, Ishizuki Y, Nagasaka A: Changes in free radical scavengers and lipid peroxide in thyroid glands of various thyroid disorders. Horm Metab Res 1997;29:351–354.
29.
Ademoglu E, Ozbey N, Erbil Y, Tanrikulu S, Barbaros U, Yanik BT, Bozbora A, Ozarmagan S: Determination of oxidative stress in thyroid tissue and plasma of patients with Graves’ disease. Eur J Intern Med 2006;17:545–550.
30.
Seven A, Tasan E, Inci F, Hatemi H, Burçak G: Biochemical evaluation of oxidative stress in propylthiouracil treated hyperthyroid patients. Effects of vitamin C supplementation. Clin Chem Lab Med 1998;36:767–770.
31.
Guerra LN, Moiguer S, Karner M, de Molina MC, Sreider CM, Burdman JA: Antioxidants in the treatment of Graves disease. IUBMB Life 2001;51:105–109.
32.
Vrca VB, Skreb F, Cepelak I, Romic Z, Mayer L: Supplementation with antioxidants in the treatment of Graves’ disease; the effect on glutathione peroxidase activity and concentration of selenium. Clin Chim Acta 2004;341:55–63.
33.
Bahn RS: Graves’ ophthalmopathy. New Engl J Med 2010;362:726–738.
34.
Bartalena L, Tanda ML, Piantanida E, Lai A: Oxidative stress and Graves’ ophthalmopathy: in vitro studies and therapeutic implications. Biofactors 1003;19:155–163.
35.
Burch HB, Lahiri S, Bahn RS, Barnes S: Superoxide radical production stimulates retroocular fibroblast proliferation in Graves’ ophthalmopathy. Exp Eye Res 1997;65:311–316.
36.
Heufelder AE, Wenzel BE, Bahn RS: Methimazole and propylthiouracil inhibit the oxygen free radical-induced expression of a 72 kilodalton heat shock protein in Graves’ retroocular fibroblasts. J Clin Endocrinol Metab 1992;74:737–742.
37.
Lu R, Wang P, Wartofsky L, Sutton BD, Zweier JL, Bahn RS, Garrity J, Burman KD: Oxygen free radicals in interleukin-1beta-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves’ ophthalmopathy patients. Thyroid 1999;9:297–303.
38.
Hondur A, Konuk O, Dincel AS, Bilgihan A, Unal M, Hasanreisoglu B: Oxidative stress and antioxidant activity in orbital fibroadipose tissue in Graves’ ophthalmopathy. Curr Eye Res 2008;33:421–427.
39.
Tsai CC, Wu SB, Cheng CY, Kao SC, Kau HC, Chiou SH, Hsu WM, Wei YH: Increased oxidative DNA damage, lipid peroxidation, and reactive oxygen species in cultured orbital fibroblasts from patients with Graves’ ophthalmopathy: evidence that oxidative stress has a role in this disorder. Eye (Lond) 2010;24:1520–1525.
40.
Tsai CC, Wu SB, Cheng CY, Kao SC, Kau HC, Lee SM, Wei YH: Increased response to oxidative stress challenge in Graves’ ophthalmopathy orbital fibroblasts. Mol Vis 2011;17:2782–2788.
41.
Tsai CC, Kao SC, Cheng CY, Kau HC, Hsu WM, Lee CF, Wei YH: Oxidative stress change by systemic corticosteroid treatment among patients having active Graves ophthalmopathy. Arch Ophthalmol 2007;125:1652–1656.
42.
Tsai CC, Cheng CY, Liu CY, Kao SC, Kau HC, Hsu WM, Wei YH: Oxidative stress in patients with Graves’ ophthalmopathy: relationship between oxidative DNA damage and clinical evolution. Eye (Lond) 2009;23:1725–1730.
43.
Akarsu E, Buyukhatipoglu H, Aktaran S, Kurtul N: Effects of pulse methylprednisolone and oral methylprednisolone treatments on serum levels of oxidative stress markers in Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 2011;74:118–124.
44.
Bouzas EA, Karadimas P, Mastorakos G, Koutras DA: Antioxidant agents in the treatment of Graves’ ophthalmopathy. Am J Ophthalmol 2000;129:618–622.
45.
Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W, European Group on Graves’ Orbitopathy: Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 2011;364:1920–1931.
© 2012 European Thyroid Association Published by S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.